

Animal : **Beline 2 von der Unstrut-Aue**

| | | | |
|-----------------------|-----------------------------|----------------------|--|
| Identification No. : | 276 099 200 542 848 | Owner : | Silke und Thomas SCHORCHT |
| Breed : | Bernese Mountain Dog | Sample No. : | E00827218 (sampled on 04/05/2023) |
| Gender : | Female | Result code : | A00035701 |
| Birth date: | 28/03/2023 | Sampler : | Saskia TOPFER |
| Pedigree : | | | Sample authenticated |
| Result validated on : | 22/05/2023 | Document issued on : | 22/05/2023 |

| DISEASES | GENE Mutation | Expression mode | RESULT | EXPRESSION | TRANSMISSION |
|-------------------------------|--------------------------|----------------------|--------------------------|------------|--------------|
| Degenerative Myelopathy | | | | | |
| DM | SOD1 c.118G>A | Autosomal recessive | Normal homozygous | ✓ | ✓ |
| DM-sod1B | SOD1 c.52A>T | Autosomal recessive | Normal homozygous | ✓ | ✓ |
| von Willebrand Disease (vWD1) | | | | | |
| | VWF c.7142C>T | Autosomal recessive | Normal homozygous | ✓ | ✓ |
| Multidrug Sensitivity (MDR1) | | | | | |
| | MDR1 c.227_230delATAG | Autosomal codominant | Normal homozygous | ✓ | ✓ |

| INTERPRETATION OF THE RESULT | EXPRESSION | TRANSMISSION |
|---|--|---|
| <p>Normal homozygous : the animal carries 2 normal copies of the gene.</p> <p>Heterozygous : the animal carries a normal copy and a defective copy of the gene.</p> <p>Mutated homozygous : the animal carries 2 defective copies of the gene.</p> | <p>✓ The animal will not develop the form of the disease associated to the tested mutation.</p> <p>! The animal will develop the disease without being able to predict the age of onset or severity of symptoms.</p> | <p>The animal does not transmit the tested mutation.</p> <p>The animal will transmit the tested mutation to all or part of its offspring. Reproduction is to be avoided or adapted according to the disease and the associated frequency.</p> |

Animal : **Beline 2 von der Unstrut-Aue**

| | | | |
|-----------------------|-----------------------------|----------------------|--|
| Identification No. : | 276 099 200 542 848 | Owner : | Silke und Thomas SCHORCHT |
| Breed : | Bernese Mountain Dog | Sample No. : | E00827218 (sampled on 04/05/2023) |
| Gender : | Female | Result code : | A00035701 |
| Birth date: | 28/03/2023 | Sampler : | Saskia TOPFER |
| Pedigree : | | | Sample authenticated |
| Result validated on : | 22/05/2023 | Document issued on : | 22/05/2023 |

MORPHOLOGICAL TRAITS

| | GENE Mutation | Expression mode | RESULT |
|--------------------------------------|-------------------------|---------------------------|------------------------------|
| Curly or Wavy Coat (c ¹) | KRT71 c.451C>T | Autosomal dominant | Non-carrier (C/C) |
| Polydactyly | LMBR1 DC-2 | Autosomal dominant | Homozygous polydactyl |
| Shedding | MC5R g.24430748C>T | Autosomal codominant | High shedding |

Animal : **Beline 2 von der Unstrut-Aue**

| | | | |
|-----------------------|-----------------------------|----------------------|--|
| Identification No. : | 276 099 200 542 848 | Owner : | Silke und Thomas SCHORCHT |
| Breed : | Bernese Mountain Dog | Sample No. : | E00827218 (sampled on 04/05/2023) |
| Gender : | Female | Result code : | A00035701 |
| Birth date: | 28/03/2023 | Sampler : | Saskia TOPFER |
| Pedigree : | | | Sample authenticated |
| Result validated on : | 22/05/2023 | Document issued on : | 22/05/2023 |

RISK FACTORS

| | Expression mode | RESULT |
|---------------------|------------------------------|----------------|
| Histiocytic Sarcoma | Polygenic and multifactorial | Index B |

Index A: The tested dog has a four times lower risk of developing Histiocytic Sarcoma.

Index B: Neutral index - No higher or lower risk of developing Histiocytic Sarcoma.

Index C: The tested dog has a four times higher risk of developing Histiocytic Sarcoma. The risk of the markers associated with the disease being transmitted to offspring is greatly increased. An Index C dog with a number of other positive qualities should not be removed from the breeding programme, rather it is necessary to adapt its matings. It is recommended to use the HSIMS tools to assess the best partners.

Explanation

This genetic test should be just one of the many selection criteria. It is important within a breeding population to give priority to individuals with the best index but is also of the utmost importance when selecting breeding pairs that sufficient genetic diversity is maintained in the breed.

This genetic test for Histiocytic Sarcoma is based on 9 genetic markers (Panel SH0912) identified from scientific research on Histiocytic Sarcoma on Bernese Mountain Dogs carried out by the Canine Genetics Team of the CNRS of Rennes, France. The methods used to calculate the genetic index were based on a population of 1081 European dogs, mainly from France. The test for Histiocytic Sarcoma has three possible results expressed as an index: index A, the individual tested has a four times lower risk of developing Histiocytic Sarcoma ; index B means neutral index ; index C, the individual tested has a four times higher risk of developing Histiocytic Sarcoma. This genetic test is simply a probability test, and this must be clearly accepted by the user.

This genetic test is designed solely to be a tool to help breeders in their breeding decisions. As a probability test, the test SH is subject to error and should not therefore be used, under no circumstances, as a commercial or advertising point by breeders.